Turtle, Cameron J <br/><br/>
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.  [electronic resource] 

 -  Science translational medicine  09 2016 
 - 355ra116 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1946-6242 
<br/><br/><label>Standard No.: </label>10.1126/scitranslmed.aaf8621  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Biomarkers, Tumor--metabolism<br/>CD4-Positive T-Lymphocytes--immunology<br/>CD8-Positive T-Lymphocytes--immunology<br/>Cell Proliferation<br/>Cyclophosphamide--pharmacology<br/>Female<br/>Humans<br/>Immunotherapy--adverse effects<br/>Lymphocyte Depletion<br/>Lymphocyte Subsets--immunology<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Receptors, Antigen, T-Cell--immunology<br/>Syndrome<br/>Transgenes<br/>Treatment Outcome<br/>Vidarabine--analogs & derivatives<br/>Young Adult